Skip to main content
Haisco Pharmaceutical Group Co.,Ltd logo

Haisco Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 002653 ISIN · CNE100001BC7 LEI · 300300GRLH34A8GPJ639 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,439 across all filing types
Latest filing 2023-07-13 Earnings Release
Country CN China
Listing Shenzhen Stock Exchange 002653

About Haisco Pharmaceutical Group Co.,Ltd

https://www.haisco.com

Haisco Pharmaceutical Group Co.,Ltd. focuses on the research, development, production, and commercialization of innovative drugs and high-end generic pharmaceuticals. The company maintains a specialized portfolio across therapeutic areas including anesthesia, parenteral nutrition, anti-infection, cardiovascular health, and endocrine disorders. Key products include advanced anesthetic agents and specialized nutritional injections designed for clinical use. Haisco prioritizes technological innovation through a dedicated R&D infrastructure, targeting the development of small molecule chemical drugs and complex delivery systems. Its operations emphasize high-standard manufacturing processes and the integration of clinical research to address complex medical requirements. The company aims to provide therapeutic solutions that enhance patient care through a commitment to scientific excellence and product quality.

Recent filings

Filing Released Lang Actions
2023年半年度业绩预告
Earnings Release Classification · 95% confidence The document is a performance forecast for the half-year period ending June 30, 2023, issued by the company. It provides estimated financial results such as net profit and earnings per share, but explicitly states that the financial data have not been audited and that detailed financial data will be disclosed in the company's 2023 half-year report. This type of document is a preliminary earnings forecast or earnings guidance rather than a full interim or quarterly report containing actual financial statements. Therefore, it fits best under the category of Earnings Release (ER), which covers initial announcements of quarterly or periodical financial results with key highlights only. The document length is short and it is not a report publication announcement or certification. Hence, the classification is ER with high confidence. H1 2023
2023-07-13 Chinese
第四届董事会第五十次会议决议公告
Board/Management Information Classification · 95% confidence The document is a board meeting resolution announcement from 海思科医药集团股份有限公司, detailing the approval of a loan application by the board of directors. It includes voting results and procedural compliance statements. The content focuses on board decisions rather than financial results, audit opinions, or shareholder voting outcomes. It is not a full annual or interim report, nor an earnings release or proxy statement. The document is short (630 characters) and is a formal announcement of a board resolution, which fits the category of Board/Management Information (MANG).
2023-06-26 Chinese
关于安能特殊医学用途全营养配方食品 获得特殊医学用途配方食品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of a registration certificate for a special medical nutritional product. It includes product details, regulatory approval information, and a risk warning for investors. There is no financial data, no mention of financial results, no discussion of management changes, no voting results, and no indication of a report publication. The document is a regulatory announcement about product certification, which fits best under Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories.
2023-06-26 Chinese
关于获得创新药HSK31679片新适应症《临床试验通知书》的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by the company Haishike Pharmaceutical Group Co., Ltd. regarding the approval of a new clinical trial indication for their innovative drug HSK31679 tablets by the National Medical Products Administration. It includes details about the drug, the clinical trial approval, and risk warnings for investors. The document is short (893 characters) and serves as an official notification of a regulatory approval event rather than a detailed financial or management report. It does not contain financial statements, management discussion, or detailed investor presentation content. It is not a report itself but an announcement of a regulatory event related to drug approval. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-06-25 Chinese
关于获得创新药HSK21542片IND申请《受理通知书》的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a pharmaceutical company about receiving an acceptance notice from the National Medical Products Administration for an IND (Investigational New Drug) application for a new drug. It includes details about the drug, regulatory acceptance, and risk warnings. The document is short (880 characters) and serves as an official announcement of a regulatory event rather than a detailed report or financial statement. It does not contain financial data, management discussion, or detailed report content. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-06-20 Chinese
第四届董事会第四十九次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of a board meeting resolution by the company 海思科医药集团股份有限公司. It details the approval of a proposal to sell part of the company's shares in another company, including voting results and authorization details. There is no financial data, no mention of annual or quarterly reports, no audit information, and no presentation materials. The document is an official announcement of a board decision, which fits the category of Board/Management Information (MANG). The document length is short and it is not a report publication announcement or certification. Therefore, the classification is MANG with high confidence.
2023-06-18 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.